生殖器区域使用爽身粉与卵巢癌之间的关系，这一成果由美国国家癌症研究所Nicolas Wentzensen联合美国国立环境健康科学研究所Katie M. O’Brien研究团队取得。相关论文发表在2020年1月7日出版的《美国医学会杂志》上。
Title: Association of Powder Use in the Genital Area With Risk of Ovarian Cancer
Author: Katie M. O’Brien, Shelley S. Tworoger, Holly R. Harris, Garnet L. Anderson, Clarice R. Weinberg, Britton Trabert, Andrew M. Kaunitz, Aimee A. D’Aloisio, Dale P. Sandler, Nicolas Wentzensen
Importance The relationship between use of powder in the genital area and ovarian cancer is not established. Positive associations reported in case-control studies have not been confirmed in cohort studies.
Objective To estimate the association between use of powder in the genital area and ovarian cancer using prospective observational data.
Design, Setting, and Participants Data were pooled from 4 large, US-based cohorts: Nurses’ Health Study (enrollment 1976; follow-up 1982-2016; n = 81?869), Nurses’ Health Study II (enrollment 1989; follow-up 2013-2017; n = 61?261), Sister Study (enrollment 2003-2009; follow-up 2003-2017; n = 40?647), and Women’s Health Initiative Observational Study (enrollment 1993-1998; follow-up 1993-2017; n = 73?267).
Exposures Ever, long-term (≥20 years), and frequent (≥1/week) use of powder in the genital area.
Main Outcomes and Measures The primary analysis examined the association between ever use of powder in the genital area and self-reported incident ovarian cancer. Covariate-adjusted hazard ratios (HRs) and 95% CIs were estimated using Cox proportional hazards models.
Results The pooled sample included 252?745 women (median age at baseline, 57 years) with 38% self-reporting use of powder in the genital area. Ten percent reported long-term use, and 22% reported frequent use. During a median of 11.2 years of follow-up (3.8 million person-years at risk), 2168 women developed ovarian cancer (58 cases/100?000 person-years). Ovarian cancer incidence was 61 cases/100?000 person-years among ever users and 55 cases/100?000 person-years among never users (estimated risk difference at age 70 years, 0.09% [95% CI, −0.02% to 0.19%]; estimated HR, 1.08 [95% CI, 0.99 to 1.17]). The estimated HR for frequent vs never use was 1.09 (95% CI, 0.97 to 1.23) and for long-term vs never use, the HR was 1.01 (95% CI, 0.82 to 1.25). Subgroup analyses were conducted for 10 variables; the tests for heterogeneity were not statistically significant for any of these comparisons. While the estimated HR for the association between ever use of powder in the genital area and ovarian cancer risk among women with a patent reproductive tract was 1.13 (95% CI, 1.01 to 1.26), the P value for interaction comparing women with vs without patent reproductive tracts was .15.
Conclusions and Relevance In this analysis of pooled data from women in 4 US cohorts, there was not a statistically significant association between use of powder in the genital area and incident ovarian cancer. However, the study may have been underpowered to identify a small increase in risk.